HDAC9 and neoplasm: In an A549 xenograft model in nude mice, compound 144 exhibited 65.4% tumor growth inhibition when given orally at 100 mg/kg/day for 21 days, while tumor growth inhibition values of 57.3% and 44.0% were observed for the known HDAC and MDM2 inhibitors SAHA and Nutlin-3, respectively, when given by the same route and dosing regimen.